

# Marcello Maida

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4785851/publications.pdf>

Version: 2024-02-01

168  
papers

5,416  
citations

81839

39  
h-index

95218

68  
g-index

172  
all docs

172  
docs citations

172  
times ranked

7486  
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 217-221.	0.9	9
2	Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. <i>Digestive and Liver Disease</i> , 2022, 54, 183-191.	0.4	7
3	Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, .	0.8	2
4	EUS-guided choledochoduodenostomy for malignant distal biliary obstruction after failed ERCP: a retrospective nationwide analysis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 896-904.e1.	0.5	29
5	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. <i>Digestive and Liver Disease</i> , 2022, 54, 452-460.	0.4	38
6	Use of catheter-based cholangioscopy in the diagnosis of indeterminate stenosis: a multi-centre experience. <i>Minerva Gastroenterology</i> , 2022, , .	0.3	1
7	Authors' reply to "Use of restrictive iron transfusion strategy in IBD: one size does not fit all". <i>European Journal of Gastroenterology and Hepatology</i> , 2022, Publish Ahead of Print, .	0.8	0
8	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2022, 54, 1215-1221.	0.4	3
9	Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data. <i>Gastroenterology Insights</i> , 2022, 13, 117-126.	0.7	3
10	Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease. <i>Digestive and Liver Disease</i> , 2022, 54, 629-634.	0.4	8
11	Definition of a hospital volume threshold to optimize outcomes after drainage of pancreatic fluid collections with lumen-apposing metal stents: a nationwide cohort study. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 1158-1172.	0.5	14
12	Perceived Feasibility of Endoscopic Ultrasound-Guided Gastroenteric Anastomosis: An Italian Survey. <i>Medicina (Lithuania)</i> , 2022, 58, 532.	0.8	2
13	Real-life multicentre study of lumen-apposing metal stent for EUS-guided drainage of pancreatic fluid collections. <i>Gut</i> , 2022, 71, 1050-1052.	6.1	14
14	Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Viruses</i> , 2022, 14, 986.	1.5	37
15	Quality of endoscopic screening for colorectal cancer in Italy: A national survey. <i>Digestive and Liver Disease</i> , 2022, 54, 1410-1418.	0.4	3
16	SARS-CoV-2 infection in patients with a normal or abnormal liver. <i>Journal of Viral Hepatitis</i> , 2021, 28, 4-11.	1.0	29
17	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	1.9	69
18	Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. <i>Gut</i> , 2021, 70, 1241-1243.	6.1	8

#	ARTICLE	IF	CITATIONS
19	Effectiveness and safety of underwater techniques in gastrointestinal endoscopy: a comprehensive review of the literature. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 37-51.	1.3	19
20	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110106.	1.4	13
21	Could Chronic Idiopathic Intestinal Pseudo-Obstruction Be Related to Viral Infections?. <i>Journal of Clinical Medicine</i> , 2021, 10, 268.	1.0	7
22	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	4.2	6
23	BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN'S PATIENTS TREATED WITH BIOLOGICS: A NEW PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES. <i>Inflammatory Bowel Diseases</i> , 2021, 27, S58-S58.	0.9	0
24	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	4.2	31
25	COVID-19 vaccine: Call for employees in international transportation industries and international travelers as the first priority in global distribution. <i>Open Medicine (Poland)</i> , 2021, 16, 134-138.	0.6	4
26	BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN'S PATIENTS TREATED WITH BIOLOGICS: A NEW PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES. <i>Gastroenterology</i> , 2021, 160, S79.	0.6	0
27	New Therapeutic Molecules and their Metabolism in Gastroenterology- Part II. <i>Current Drug Metabolism</i> , 2021, 22, 84-84.	0.7	0
28	Effectiveness and Tolerability of Very-low Volume Preparation for Colonoscopy: A Narrative Review. <i>Current Drug Metabolism</i> , 2021, 22, 85-88.	0.7	2
29	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021, 13, 1673.	1.7	21
30	A cost-effective plan for global testing - an infection rate stratified, algorithm guided, multiple-level, continuously pooled testing strategy. <i>Science of the Total Environment</i> , 2021, 765, 144251.	3.9	8
31	Su453 BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN'S DISEASE PATIENTS TREATED WITH BIOLOGICS: A NEW PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES. <i>Gastroenterology</i> , 2021, 160, S-697-S-698.	0.6	0
32	Young gastrointestinal angle: E-learning in gastroenterology: Future is now. <i>United European Gastroenterology Journal</i> , 2021, 9, 635-637.	1.6	2
33	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). <i>Journal of Hepatology</i> , 2021, 74, 1225-1233.	1.8	42
34	ID: 3523449 EUS-GUIDED GALLBLADDER DRAINAGE USING LUMEN-APPOSING METAL STENT AS RESCUE TREATMENT FOR MALIGNANT DISTAL BILIARY OBSTRUCTION: A LARGE MULTICENTER EXPERIENCE. <i>Gastrointestinal Endoscopy</i> , 2021, 93, AB244-AB245.	0.5	2
35	ID: 3521184 EUS-GUIDED GALLBLADDER DRAINAGE USING A LUMEN APPOSING METAL STENT FOR ACUTE CHOLECYSTITIS: RESULTS OF A MULTICENTER STUDY. <i>Gastrointestinal Endoscopy</i> , 2021, 93, AB268.	0.5	0
36	Blood-based prognostic biomarkers in Crohn's Disease patients on biologics: a promising tool to predict endoscopic outcomes. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1133-1141.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	0.2	2
38	Microbiota Gut-Brain Axis in Ischemic Stroke: A Narrative Review with a Focus about the Relationship with Inflammatory Bowel Disease. <i>Life</i> , 2021, 11, 715.	1.1	13
39	Digital single-operator cholangioscopy in treating difficult biliary stones: results from a multicenter experience. <i>Minerva Gastroenterology</i> , 2021, , .	0.3	1
40	Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2021, 53, 1171-1177.	0.4	6
41	PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD). <i>Digestive and Liver Disease</i> , 2021, 53, S88.	0.4	0
42	AF.141 EUS-GUIDED GALLBLADDER DRAINAGE USING A LUMENAPPPOSING METAL STENT FOR ACUTE CHOLECYSTITIS: RESULTS OF A MULTICENTER STUDY. <i>Digestive and Liver Disease</i> , 2021, 53, S201.	0.4	0
43	OC.09.8 BLOOD-BASED PROGNOSTIC BIOMARKERS IN CROHN'S PATIENTS TREATED WITH BIOLOGICS: A NEW PROMISING TOOL TO PREDICT ENDOSCOPIC OUTCOMES. <i>Digestive and Liver Disease</i> , 2021, 53, S130-S131.	0.4	0
44	Upper gastrointestinal tract involvement in Crohn's disease: A relevant yet underestimated problem.. <i>Digestive and Liver Disease</i> , 2021, 53, 1546-1547.	0.4	0
45	Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	0.8	30
46	Surveillance strategies for precancerous gastric conditions after <i>Helicobacter pylori</i> eradication: There is still need for a tailored approach. <i>World Journal of Gastroenterology</i> , 2021, 27, 8033-8039.	1.4	0
47	An Unusual Presentation of Crohn's Disease Diagnosed Following Accidental Ingestion of Fruit Pits: Report of Two Cases and Review of the Literature. <i>Life</i> , 2021, 11, 1415.	1.1	2
48	Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 193-203.	1.4	33
49	Screening of gastrointestinal cancers during COVID-19: a new emergency. <i>Lancet Oncology</i> , The, 2020, 21, e338.	5.1	16
50	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. <i>Cancers</i> , 2020, 12, 2132.	1.7	18
51	GI Training in the COVID-19 Era: A Problem of Global Concern. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3405-3406.	1.1	2
52	T05.01.13 EFFECTIVENESS AND SAFETY OF NER1006 VERSUS STANDARD BOWEL PREPARATIONS: A META-ANALYSIS OF THREE RANDOMISED PHASE 3 CLINICAL TRIALS. <i>Digestive and Liver Disease</i> , 2020, 52, S143-S144.	0.4	0
53	Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 851-863.	1.1	7
54	Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: A national survey. <i>Digestive and Liver Disease</i> , 2020, 52, 808-815.	0.4	54

#	ARTICLE	IF	CITATIONS
55	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	1.1	29
56	Impact of COVID-19 outbreak on clinical practice and training of young gastroenterologists: A European survey. Digestive and Liver Disease, 2020, 52, 1396-1402.	0.4	47
57	Effectiveness and safety of NER1006 versus standard bowel preparations: A meta-analysis of randomized phase-3 clinical trials. Digestive and Liver Disease, 2020, 52, 833-839.	0.4	14
58	Tenapanor for the treatment of irritable bowel syndrome with constipation. Expert Review of Clinical Pharmacology, 2020, 13, 473-479.	1.3	7
59	Incidence of hepatocellular carcinoma after HCV eradication: assessing the risk. Hepatobiliary Surgery and Nutrition, 2020, 9, 255-256.	0.7	0
60	Current challenges and future needs of clinical and endoscopic training in gastroenterology: a European survey. Endoscopy International Open, 2020, 08, E525-E533.	0.9	13
61	Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 253-255.	0.5	4
62	New Therapeutic Molecules and their Metabolism in Gastroenterology. Current Drug Metabolism, 2020, 21, 246-246.	0.7	1
63	Emerging artificial intelligence applications in gastroenterology: A review of the literature. Artificial Intelligence in Gastrointestinal Endoscopy, 2020, 1, 6-18.	0.2	2
64	Effectiveness of very low-volume preparation for colonoscopy: A prospective, multicenter observational study. World Journal of Gastroenterology, 2020, 26, 1950-1961.	1.4	29
65	Use of artificial intelligence in improving adenoma detection rate during colonoscopy: Might both endoscopists and pathologists be further helped. World Journal of Gastroenterology, 2020, 26, 5911-5918.	1.4	27
66	Management of antiplatelet or anticoagulant therapy in endoscopy: A review of literature. World Journal of Gastrointestinal Endoscopy, 2020, 12, 172-192.	0.4	2
67	Emerging artificial intelligence applications in gastroenterology: A review of the literature. Artificial Intelligence in Gastrointestinal Endoscopy, 2020, 1, 19-27.	0.2	0
68	Gastrointestinal tract injuries after thermal ablative therapies for hepatocellular carcinoma: A case report and review of the literature. World Journal of Gastroenterology, 2020, 26, 5375-5386.	1.4	3
69	P.05.51 REFRACTORY GAVE TREATED WITH RADIOFREQUENCY ABLATION BY THROUGH-THE-SCOPE CATHETER: THREE CASES OF COMPLETE RESPONSE. Digestive and Liver Disease, 2019, 51, e205.	0.4	0
70	Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials. Future Oncology, 2019, 15, 3411-3422.	1.1	21
71	P.05.24 WHAT DOES A ILEOCOLONIC WALL THICKENING MEAN? RESULTS FROM A RETROSPECTIVE STUDY. Digestive and Liver Disease, 2019, 51, e194.	0.4	0
72	OC.13.3 EFFECTIVENESS AND TOLERABILITY OF VERY LOWVOLUME PREPARATION FOR COLONOSCOPY: A PROSPECTIVE, MULTICENTER STUDY. Digestive and Liver Disease, 2019, 51, e113.	0.4	0

#	ARTICLE	IF	CITATIONS
73	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019, 39, 1478-1489.	1.9	41
74	P.01.22 A NATIONAL SURVEY ON GASTROENTEROLOGY TRAINING IN ITALY: CURRENT LANDSCAPE AND FUTURE NEEDS. <i>Digestive and Liver Disease</i> , 2019, 51, e142.	0.4	0
75	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 603-610.	1.0	12
76	145â€fEffectiveness and Tolerability of Very Low-Volume Preparation for Colonoscopy: A Prospective, Multicenter Observational Study. <i>American Journal of Gastroenterology</i> , 2019, 114, S87-S88.	0.2	0
77	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 987-997.	0.9	17
78	Quality measures improving endoscopic screening of colorectal cancer: a review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 223-235.	1.1	15
79	146â€fSafety of NER1006 in the Elderly: A Post-Hoc Analysis of a Prospective, Multicenter Cohort. <i>American Journal of Gastroenterology</i> , 2019, 114, S88-S88.	0.2	0
80	144â€fEfficacy and Safety of NER1006 Versus Standard Bowel Preparations: A Meta-Analysis of Randomized Phase 3 Clinical Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, S85-S85.	0.2	0
81	Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 307-309.	1.1	1
82	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4.	0.6	291
83	Faecal Microbiota Transplantation as Emerging Treatment in European Countries. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1050, 177-195.	0.8	7
84	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018, 67, 1784-1796.	3.6	93
85	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Annals of Hepatology</i> , 2018, 17, 110-118.	0.6	20
86	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. <i>Liver International</i> , 2018, 38, 2108-2116.	1.9	20
87	Efficacy of different faecal microbiota transplantation protocols for <i>Clostridium difficile</i> infection: A systematic review and metaâ€analysis. <i>United European Gastroenterology Journal</i> , 2018, 6, 1232-1244.	1.6	137
88	Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study. <i>Future Oncology</i> , 2018, 14, 3049-3058.	1.1	6
89	Binge Drinking among adolescents is related to the development of Alcohol Use Disorders: results from a Cross-Sectional Study. <i>Scientific Reports</i> , 2018, 8, 12624.	1.6	50
90	Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma?. <i>Recenti Progressi in Medicina</i> , 2018, 109, 605-608.	0.8	1

#	ARTICLE	IF	CITATIONS
91	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1157-1166.	1.9	70
92	Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017. <i>Future Oncology</i> , 2017, 13, 1297-1300.	1.1	1
93	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	0.6	21
94	Screening of colorectal cancer: present and future. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1131-1146.	1.1	123
95	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF- $\alpha$ inhibitors and conventional immunosuppressants. <i>Digestive and Liver Disease</i> , 2017, 49, 157-162.	0.4	6
96	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 423-433.	1.9	46
97	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017, 37, 259-270.	1.9	67
98	Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 105-110.	1.8	56
99	Radiofrequency Ablation for Treatment of Refractory Gastric Antral Vascular Ectasia: A Systematic Review of the Literature. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-5.	0.7	15
100	New endoscopy advances to refine adenoma detection rate for colorectal cancer screening: None is the winner. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 402-406.	0.8	8
101	Refining prognosis after transarterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 729-736.	1.9	62
102	Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 385-399.	1.9	59
103	Years of life that could be saved from prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 814-824.	1.9	20
104	TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016, 36, 198-204.	1.9	15
105	Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 310-311.	1.9	8
106	Screening and surveillance for hepatocellular carcinoma: perspective of a new era?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1291-1302.	1.1	4
107	Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. <i>Journal of Hepatology</i> , 2016, 65, 861-862.	1.8	77
108	Neovascularization-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. <i>Gut</i> , 2016, 65, 861-869.	6.1	207

#	ARTICLE	IF	CITATIONS
109	Curative therapies for hepatocellular carcinoma: an update and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 169-175.	1.1	8
110	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016, 111, 70-77.	0.2	59
111	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016, 150, 145-155.e4.	0.6	201
112	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. <i>Current Molecular Medicine</i> , 2016, 16, 721-737.	0.6	13
113	Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. <i>Hepatitis Monthly</i> , 2016, 16, e31681.	0.1	4
114	Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. <i>Digestive Diseases</i> , 2015, 33, 668-674.	0.8	10
115	The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 62, 1101-1110.	3.6	183
116	Genetic background in nonalcoholic fatty liver disease: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2015, 21, 11088.	1.4	66
117	Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-7.	0.7	22
118	Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 147-150.	1.1	1
119	Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. <i>Hepatology</i> , 2015, 62, 784-791.	3.6	110
120	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	1.8	184
121	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2015, 47, 324-330.	0.4	43
122	Recurrence of hepatocellular carcinoma after liver transplantation: an update. <i>Future Oncology</i> , 2015, 11, 2923-2936.	1.1	40
123	Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?. <i>Future Oncology</i> , 2015, 11, 2371-2373.	1.1	11
124	Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. <i>World Journal of Hepatology</i> , 2015, 7, 2053.	0.8	12
125	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 333-341.	1.8	110
126	Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 878-884.e1.	2.4	13



#	ARTICLE	IF	CITATIONS
127	Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 523-529.	1.8	67
128	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. <i>Cancer</i> , 2014, 120, 2150-2157.	2.0	56
129	Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 831-845.	1.1	21
130	Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. <i>Digestive and Liver Disease</i> , 2014, 46, 1116-1120.	0.4	44
131	Post sorafenib survival in patients with advanced hepatocellular carcinoma: The role of tumor progression and liver impairment. <i>Digestive and Liver Disease</i> , 2014, 46, e35-e36.	0.4	0
132	The histological or ultrasonographic detection of steatosis affects the performance of LSM in patients with chronic HCV genotype 1 infection. <i>Digestive and Liver Disease</i> , 2014, 46, e20.	0.4	0
133	Staging systems of hepatocellular carcinoma: A review of literature. <i>World Journal of Gastroenterology</i> , 2014, 20, 4141.	1.4	94
134	Hepatobiliary and Pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1257-1257.	1.4	3
135	Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1355-1361.	1.1	14
136	Treatment of hepatocellular carcinoma: present and future. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 469-479.	1.1	23
137	Assessment of treatment response in hepatocellular carcinoma: a review of the literature. <i>Future Oncology</i> , 2013, 9, 845-854.	1.1	8
138	Metabolic Factors and Chronic Hepatitis C: A Complex Interplay. <i>BioMed Research International</i> , 2013, 1-12.	0.9	26
139	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1046-1054.	3.6	89
140	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. <i>World Journal of Hepatology</i> , 2013, 5, 685.	0.8	29
141	Imaging appearance of treated hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2013, 5, 417.	0.8	29
142	Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response. <i>PLoS ONE</i> , 2013, 8, e70016.	1.1	29
143	Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. <i>World Journal of Hepatology</i> , 2013, 5, 696.	0.8	9
144	Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist. <i>World Journal of Hepatology</i> , 2013, 5, 288.	0.8	5

#	ARTICLE	IF	CITATIONS
145	Progressive multi-organ expression of immunoglobulin G4-related disease: A case report. <i>World Journal of Hepatology</i> , 2013, 5, 336.	0.8	4
146	Chemoprevention for hepatocellular carcinoma: the role of statins. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 1-3.	0.7	0
147	Causes of and Prevention Strategies for Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 374-383.	0.8	49
148	Imaging findings of liver resection using a bipolar radiofrequency electro-surgical device—Initial observations. <i>European Journal of Radiology</i> , 2012, 81, 663-670.	1.2	8
149	Multifocal Pyoderma Gangrenosum Resistant to Infliximab in Active Ulcerative Colitis: Don't Forget the Role of Cyclosporin. <i>Inflammatory Bowel Diseases</i> , 2012, 18, E1594-E1595.	0.9	10
150	Should cirrhosis change our attitude towards treating non-hepatic cancer?. <i>Liver International</i> , 2012, 32, 21-27.	1.9	21
151	Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. <i>World Journal of Hepatology</i> , 2012, 4, 256.	0.8	67
152	Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. <i>Liver International</i> , 2011, 31, 507-515.	1.9	70
153	Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. <i>Hepatology</i> , 2011, 54, 2055-2063.	3.6	321
154	Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1807-1816.	1.1	22
155	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. <i>Hepatology</i> , 2010, 51, 1274-1283.	3.6	374
156	Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, 729-734.	0.4	12
157	Minor Hepatic Resection Using Heat Coagulative Necrosis. <i>American Surgeon</i> , 2009, 75, 1213-1219.	0.4	7
158	Hyperferritinemia is a risk factor for steatosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2132.	1.4	32
159	Multimodal approaches to the treatment of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 159-169.	8.2	66
160	Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance. <i>Digestive Diseases</i> , 2009, 27, 142-147.	0.8	31
161	Prognostic scores for hepatocellular carcinoma: none is the winner. <i>Liver International</i> , 2009, 29, 478-480.	1.9	39
162	Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. <i>Journal of Hepatology</i> , 2009, 51, 675-681.	1.8	22

#	ARTICLE	IF	CITATIONS
163	Needle track seeding following percutaneous procedures for hepatocellular carcinoma. World Journal of Hepatology, 2009, 1, 62.	0.8	21
164	Minor hepatic resection using heat coagulative necrosis. American Surgeon, 2009, 75, 1213-9.	0.4	6
165	Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease. Gastroenterology, 2008, 135, 1500-1509.	0.6	84
166	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. Journal of Hepatology, 2005, 42, 535-540.	1.8	101
167	Model for end stage liver disease for prediction of mortality in people with cirrhosis. The Cochrane Library, 0, , .	1.5	0
168	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International, 0, , .	0.2	3